For Immediate Release
Chicago, IL – October 25, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla, Inc. (
TSLA Quick Quote TSLA - Free Report) , Johnson & Johnson ( JNJ Quick Quote JNJ - Free Report) , PayPal Holdings, Inc. ( PYPL Quick Quote PYPL - Free Report) , Verizon Communications Inc. ( VZ Quick Quote VZ - Free Report) , Square, Inc. ( SQ Quick Quote SQ - Free Report) and GlaxoSmithKline plc ( GSK Quick Quote GSK - Free Report) . Here are highlights from Friday’s Analyst Blog: Top Analyst Reports for Tesla, Johnson & Johnson and PayPal
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Johnson & Johnson, and PayPal. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>>
Tesla have outperformed the Zacks Domestic Automotive industry in the year to date period (+28.5% vs. +10.1%). The Zacks analyst believes that a robust demand for Models 3 and Y has been buoying Tesla's revenues. The electric vehicle (EV) giant’s gross auto margins hit a record high in third-quarter 2021.
Tesla achieved record Q3 production and deliveries despite chip crunch. The company has also started making progress at ramping up volumes of Models S and X. Tesla’s energy generation and storage revenues as well as a low debt to capitalization ratio not only increase its financial flexibility but also boost its earnings prospects.
) read the full research report on Tesla here >>> Johnson & Johnson shares have gained +0.2% over the past six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +9.4%. Generic competition and pricing pressure continue to weigh on its margins. Though it has taken steps to resolve the talc and opioid litigations, they continue to remain a major concern for the company.
The Zacks analyst, however, believes that label expansion of drugs such as Imbruvica, Darzalex and Stelara have been boosting the company’s margins. The company is also making rapid progress with its pipeline and line extensions, with several pivotal data readouts and regulatory milestones expected in the near term.
) read the full research report on Johnson & Johnson here >>>
PayPal have gained +19.2% over the past year against the Zacks Internet Software industry’s gain of +11.3%, though the stock has lost ground lately on the Pinterest news. The Zacks analyst believes that the company has been benefiting from steady growth in total payments volume on the back of increasing net new active accounts.
Venmo’s improving monetization efforts and rising adoption rate across various platforms are aiding the total active accounts growth. Accelerating transaction revenues of PayPal are likely to continue driving revenues further. Intensifying competition in the digital payment market, foreign exchange fluctuations and interest rate related risks remain major concerns though.
) read the full research report on PayPal here >>>
Other noteworthy reports we are featuring today include Verizon, Square and GlaxoSmithKline.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.